LV14840B - Quinazolinones with triazole substituent in side chain - Google Patents
Quinazolinones with triazole substituent in side chain Download PDFInfo
- Publication number
- LV14840B LV14840B LVP-13-188A LV130188A LV14840B LV 14840 B LV14840 B LV 14840B LV 130188 A LV130188 A LV 130188A LV 14840 B LV14840 B LV 14840B
- Authority
- LV
- Latvia
- Prior art keywords
- arom
- side chain
- quinazolinones
- mmol
- triazole
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
IZGUDROJUMA APRAKSTSDESCRIPTION OF THE INVENTION
Izgudrojums attiecas uz bioorganiskās ķīmijas nozari, konkrēti, jaunu hinazolinonatriazola atvasinājumu sintēzi.The present invention relates to the field of bioorganic chemistry, in particular to the synthesis of novel quinazolinonatriazole derivatives.
Hinazolinoni ir slāpekli saturoši sešlocekļu heterocikliski savienojumi, kam ir svarīga loma medicīnisku preparātu izstrādē. Zināms liels skaits hinazolīna ciklu saturošu bioloģiski aktīvu savienojumu ar pretvēža [1], pretdrudža [2], pretiekaisuma [3] un antialerģisku [4] iedarbību.Quinazolinones are nitrogen-containing six-membered heterocyclic compounds that play an important role in the development of medicinal products. A large number of quinazoline cycle-containing biologically active compounds with anticancer [1], antipyretic [2], anti-inflammatory [3] and anti-allergic [4] effects are known.
Arvien palielinās ari triazola atvasinājumu loma farmācijas un citās ķīmijas nozarēs. Potenciāli farmaceitiski līdzekļi, kas balstīti uz 1,2,3-triazolu funkciju, ir, piemēram, klīniski pārbaudītais pretvēža līdzeklis ar pagaidu apzīmējumu CAI [5]. Organiskajā un medicīnas ķīmijā 1,2,3-triazolus izmanto kāpeptīdu saites izostērus [6].The role of triazole derivatives in the pharmaceutical and other chemical industries is also increasing. Potential pharmaceuticals based on 1,2,3-triazoles are, for example, the clinically tested anticancer agent temporarily labeled CAI [5]. In organic and medical chemistry, 1,2,3-triazoles are used as peptide bond isosters [6].
Pamatojoties uz augšminētajiem faktiem var sagaidīt, ka savstarpēji savienojot šos fragmentus - hinazolinonu un 1,2,3-triazolu, veidosies savienojumi ar pilnīgi jaunu vai modificētu bioloģisko aktivitāti. Literatūrā šāda tipa savienojumi nav aprakstīti, taču medicīnas ķīmijas jomā, kas apskata pretvēža, pretdrudža, pretiekaisuma un antialerģiskus preparātus uz hinazolīna bāzes, bioloģiskās aktivitātes modulēšanā nozīmīga loma var būt sānu ķēdes aizvietotājiem, tāpēc par izgudrojuma mērķi izvirzījām jaunu hinazolinona atvasinājumu ar triazola aizvietotāju sānu ķēdē sintēzi.Based on the above, it can be expected that the coupling of these moieties, quinazolinone and 1,2,3-triazole, will result in the formation of entirely new or modified biological activities. Compounds of this type have not been described in the literature, but in the field of medical chemistry, which deals with quinazoline based anticancer, antipyretic, anti-inflammatory and anti-allergic agents, side chain substitutions may play an important role in modulating biological activity. synthesis.
Izgudrojuma mērķis ir sintezēt jaunus hinazolinona atvasinājumus ar triazola aizvietotāju sānu ķēdē.The object of the invention is to synthesize new quinazolinone derivatives with a triazole substituent on the side chain.
Mērķis tiek sasniegts sintezējot jaunus hinazolīn-4(3//)-onus ar triazola ciklu saturošu sānu ķēdi hinazolinona cikla C(3) pozīcijā. Sintēze veikta saskaņā ar 1. shēmu, pēc kuras literatūrā zināmajam hinazolīna benzsulfonilatvasinājumam (3) tozilgrupu aizvieto ar azidogrupu un iegūto 3-azido-4(3//)-hinazolinonu (4) apstrādā ar acetilēna atvasinājumu, pielietojot Huisgena sintēzes metodi, kas pamatojas uz vara(I) katalizētu alkīnu 1,3ciklopievienošanos azīdiem. Reakciju rezultātā iegūti deviņi jauni hinazolīn-4(3H)-oni ar triazola ciklu sānu ķēdē (5), kur R ir sānu ķēdē aizvietota vai neaizvietota alkil- vai cikloalkilgrupa.The object is achieved by the synthesis of new quinazolin-4 (3 H) -ones with a triazole ring-containing side chain at the C (3) position of the quinazolinone ring. The synthesis is carried out according to Scheme 1 whereby the tosyl group of the quinazoline benzenesulfonyl derivative (3) known in the literature is replaced by an azido group and the resulting 3-azido-4 (3 H) -quinazolinone (4) is treated with an acetylene derivative using Huisgen synthesis method. on copper (I) catalyzed 1,3-cycloaddition of alkynes to azides. The reactions yielded nine new quinazolin-4 (3H) -ones with a triazole ring in the side chain (5), where R is a substituted or unsubstituted alkyl or cycloalkyl group in the side chain.
1. shēmaScheme 1
Izgudrojuma realizācijas piemēri:Examples of realization of the invention:
1. piemērs.Example 1:
3-(2-azidoetil)hinazolīh-4(37/)-ons (4)3- (2-Azidoethyl) quinazolin-4 (3 H) -one (4)
2,8 g (8 mmol) 2-(4-oksohinazolīn-3(4^-il)etil-4-metilbenzosulfonāta šķīdumam (3) 30 ml dimetilformamīda pievieno 2,6 g (40 mmol) nātrija azīda un karsē 1 stundu 60°C temperatūrā (PHS (plānā slāņa hromatogrāfija) kontrole). Reakcijas maisījumam pievieno metil-trešbutilēteri (300 ml) un mazgā ar piesātinātu nātrija hlorīda šķīdumu (10 x 20 ml). Organisko fāzi žāvē ar bezūdens nātrija sulfātu un ietvaicē pazeminātā spiedienā. Iegūst 1,7 g (99%) savienojumu 4 baltas kristāliskas vielas veidā, kuru bez attīrīšanas izmanto tālākām reakcijām. K. p. 63-64°C ^-KMRQOOMHx, CDC13), δ, ppm: 3.77 (2H, t, 7=5.7, СН2); 4.13 (2Н, t, 7=5.7, СН2); 7.53 (1Н, t, 7=6.8, arom.); 7.69 (2Н, m, arom.); 8.05 (1Н, pl.s, =CH); 8.32 (1H, d, 7=7.9, arom.).To a solution of 2.8 g (8 mmol) of 2- (4-oxoquinazolin-3 (4'-yl) ethyl 4-methylbenzosulfonate (3) in 30 ml of dimethylformamide add 2.6 g (40 mmol) of sodium azide and heat for 1 hour 60. ° C (PHS (thin layer chromatography) control) Methyl tert-butyl ether (300 mL) is added to the reaction mixture and washed with saturated sodium chloride solution (10 x 20 mL) The organic phase is dried over anhydrous sodium sulfate and evaporated under reduced pressure. 1.7 g (99%) compound 4 in the form of white crystalline substance, which without purification used for further reactions. K. p. 63-64 ° C @ -KMRQOOMHx, CDC1 3) δ ppm: 3.77 (2H, t, 7 = 5.7, С 2 ); 4.13 (2Н, t, 7 = 5.7, СН 2); 7.53 (1N, t, 7 = 6.8, arom.); 7.69 (2N, m, arom.); 8.05 (1N, pl.s, = CH); 8.32 (1H, d, J = 7.9, arom.).
2. piemērs.Example 2:
[(l,2,3-triazol-l-il)etil]hinazolm-4(37/)-°ni (5a-h)[(1,2,3-Triazol-1-yl) ethyl] quinazol-4 (37H) -N (5a-h)
A metode:Method A:
0,32 g (1,5 mmol)3-(2-azidoetil)hmazolm-4(377)-ona (4) šķīdumam 5 ml acetona pievieno 1,8 mmol alkīna, 60 mg (0,30 mmol) nātrija askorbāta šķīdumu 0,1 ml ūdens un 37,5 mg (0.15 mmol) vara sulfāta (CuSO4-5 H2O) šķīdumu 0,1 ml ūdens. Iegūto maisījumu maisa un vāra 17 stundas (PSH kontrole). Acetonu ietvaicē pazeminātā spiedienā. Atlikumu šķīdina dihlormetānā (20 ml) un mazgā ar piesātinātu nātrija hlorīda ūdens šķīdumu (3 x 10 ml). Organisko fāzi žāvē ar bezūdens nātrija sulfātu, filtrē un ietvaicē pazeminātā spiedienā. Atlikumu pārkristalizē.To a solution of 0.32 g (1.5 mmol) of 3- (2-azidoethyl) -mazol-4 (377) -one (4) in 5 ml of acetone add 1.8 mmol of alkyne, 60 mg (0.30 mmol) of sodium ascorbate solution 0.1 ml of water and 37.5 mg (0:15 mmol) of copper sulfate (CuSO4-5 H 2 O) solution of 0.1 ml of water. Stir the resulting mixture for 17 hours (PSH control). The acetone is evaporated under reduced pressure. The residue is dissolved in dichloromethane (20 ml) and washed with saturated aqueous sodium chloride solution (3 x 10 ml). The organic phase is dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure. The residue is recrystallized.
В metode:Method В:
0,32 g (1,5 mmol) 3-azidoetil)hinazolm-4(377)-ona (4) šķīdumam 5 ml tetrahidrofurāna pievieno 34 mg (0,18 mmol) varajodīda, 63 μΐ (0,36 mmol) diizopropiletilamīna un 1,8 mmol alkīnu. Iegūto maisījumu maisa un vāra 1-3 stundas (PSH kontrole). Šķīdinātāju ietvaicē pazeminātā spiedienā. Atlikumu šķīdina dihlormetānā (20 ml), mazgā ar trilona В buferšķīdumu (5 x 2 ml) un piesātinātu nātrija hlorīda šķīdumu (2x2 ml). Organisko fāzi žāvē ar bezūdens nātrija sulfātu, filtrē un ietvaicē pazeminātā spiedienā. Atlikumu pārkristalizē.To a solution of 3-azidoethyl) quinazol-4 (377) -one (4) (0.32 g, 1.5 mmol) in 5 mL of tetrahydrofuran was added 34 mg (0.18 mmol) of varaiodide, 63 μΐ (0.36 mmol) of diisopropylethylamine and 1.8 mmol of alkyne. Stir the resulting mixture for 1-3 hours (PSH control). The solvent is evaporated off under reduced pressure. The residue is dissolved in dichloromethane (20 ml), washed with trilone В buffer (5 x 2 ml) and saturated sodium chloride solution (2x2 ml). The organic phase is dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure. The residue is recrystallized.
Savienojumu 5a-h analītiskie rādītāji atspoguļoti 1. tabulā; ’H-KMR spektru dati - 2. tabulā.The analytical data for compounds 5a-h are shown in Table 1; 'H-NMR spectra data in Table 2.
' . . . . . 1. tabula [(l,2,3-Triazol-l-il)etil]hinazolīn-4(377)-onu(5a-h) analītiskie rādītāji'. . . . . Table 1 [(1,2,3-Triazol-1-yl) ethyl] quinazolin-4 (377) -one (5a-h) analytical data
2. tabula [(1,2,3-Triazol-l-il)etil]hmazolīn-4(377)-onu (5a-h) ’H-KMR spektriTable 2 [1 H-NMR Spectrum of [(1,2,3-Triazol-1-yl) ethyl] hexolin-4 (377) -one (5a-h)
LITERATŪRALITERATURE
1. G. M. Chinigo, M. Paige, S. Grindrod, E. Hamel, S. Dakshanamurthy, M. Chruszez, W. Minor, M. Brown, J. Med. Chem., 51,4620 (2008).1. G. M. Chinigo, M. Paige, S. Grindrod, E. Hamel, S. Dakshanamurthy, M. Chruszez, W. Minor, M. Brown, J. Med. Chem., 51, 4620 (2008).
2. R. Rajput, A. P. Mishra, Int.J. Pharm. Sci, 4(2), 66 (2012).2. R. Rajput, A. P. Mishra, Int.J. Pharm. Sci, 4 (2), 66 (2012).
3. M. He, N. Cheng, W. W. Gao, M. Zhang, Y. Y. Zhang, R. D. Ye, M. W. Wang, Acta Pharmacol. Sin., 32, 601 (2011).3. M. He, N. Cheng, W. W. Gao, M. Zhang, Y. Y. Zhang, R. D. Ye, M. W. Wang, Acta Pharmacol. Syn., 32, 601 (2011).
4. A. Kamal, E. V. Bharathi, J. S. Reddy, M. J. Ramaiah, D. Dastagiri, Μ. K. Reddy, A. Viswanath, T. L. Reddy, T. B. Shaik, S. N. С. V. L. Pushpavalli, Μ. P. Bhadra, Eur. J. Med. Chem., 46, 691 (2011).4. A. Kamal, E. V. Bharathi, J. S. Reddy, M. J. Ramaiah, D. Dastagiri, Μ. K. Reddy, A. Viswanath, T. L. Reddy, T. B. Shaik, S. N. С. V. L. Pushpavalli, Μ. P. Bhadra, Eur. J. Med. Chem., 46, 691 (2011).
5. Y. L. Angell, K. Burgess, Chem. Soc. Rev., 36,1674 (2007).5. Y. L. Angell, K. Burgess, Chem. Soc. Rev., 36,1674 (2007).
6. H. C. Kolb, K.B. Sharpless, Drug Discovery Today, 8,1128 (2003).6. H. C. Kolb, K.B. Sharpless, Drug Discovery Today, 8,1128 (2003).
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
LVP-13-188A LV14840B (en) | 2013-11-25 | 2013-11-25 | Quinazolinones with triazole substituent in side chain |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
LVP-13-188A LV14840B (en) | 2013-11-25 | 2013-11-25 | Quinazolinones with triazole substituent in side chain |
Publications (2)
Publication Number | Publication Date |
---|---|
LV14840A LV14840A (en) | 2014-04-20 |
LV14840B true LV14840B (en) | 2014-06-20 |
Family
ID=50480278
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LVP-13-188A LV14840B (en) | 2013-11-25 | 2013-11-25 | Quinazolinones with triazole substituent in side chain |
Country Status (1)
Country | Link |
---|---|
LV (1) | LV14840B (en) |
-
2013
- 2013-11-25 LV LVP-13-188A patent/LV14840B/en unknown
Also Published As
Publication number | Publication date |
---|---|
LV14840A (en) | 2014-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6787998B2 (en) | Method for preparing a substituted 3- (3-anilino-1-cyclohexyl-1H-benzimidazol-5-yl) propanoic acid derivative | |
AU2013246278A1 (en) | Histone deacetylases (HDAC) inhibitors | |
AU2017389794A1 (en) | Aryl hydrocarbon receptor modulator | |
Nakhi et al. | AlCl 3-mediated hydroarylation–heteroarylation in a single pot: a direct access to densely functionalized olefins of pharmacological interest | |
CZ306598B6 (en) | A method of preparation and purification of new and known polymorphs and dasatinib solvates | |
EP3328854A1 (en) | Analogs of adamantylureas as soluble epoxide hydrolase inhibitors | |
TR201802981T4 (en) | Fluorophenyl pyrazole compounds. | |
CN102443011B (en) | Levorotatory fluoroquinolone C3 diazole methyl sulfide quaternary ammonium salt, preparation method and application thereof | |
Ates‐Alagöz et al. | Synthesis and potent antimicrobial activities of some novel retinoidal monocationic benzimidazoles | |
CN106866548B (en) | 6- ring methylpyrimidine ketone hiv reverse transcriptase inhibitor, preparation method and use | |
Bobba et al. | Synthesis and biological evaluation of selective tubulin inhibitors as anti-trypanosomal agents | |
SK4592000A3 (en) | Novel carboxylic acid derivatives which carry amide side chains, production of said carboxylic acid derivatives and their use as endothelin receptor antagonists | |
CN107935996B (en) | 3, 4-dihydropyrimidine-2 (1H) - (sulfur) ketone compounds and preparation method thereof | |
WO2019240701A1 (en) | Ef2-kinase enzyme inhibiting novel compounds | |
Cheprakova et al. | Synthesis of 5-(het) aryl-and 4, 5-di (het) aryl-2-(thio) morpholinopyrimidines from 2-chloropyrimidine via SNH and cross-coupling reactions | |
LV14840B (en) | Quinazolinones with triazole substituent in side chain | |
Sachdeva et al. | An efficient synthesis of 2, 4, 7-trisubstituted pyrimido [1, 2-a][1, 3, 5] triazin-6-ones | |
CN103965203B (en) | Imidazo-[1,2-c]-quinazolin-3(2H)-one fused-heterocycle compounds and preparation method thereof | |
CN104844618A (en) | Levofloxacin (rhodanine unsaturated ketone) amide derivative and preparation method and application thereof | |
Baranov et al. | Ring-expanding rearrangement of 2-acyl-5-arylidene-3, 5-dihydro-4H-imidazol-4-ones in synthesis of flutimide analogs | |
CN106831823B (en) | A kind of Rufloxacin aldehyde thiosemicarbazone derivatives and its preparation method and application | |
CN106632323B (en) | A kind of N- methyl Moxifloxacin aldehyde thiosemicarbazone derivatives and its preparation method and application | |
CN106749009B (en) | A kind of pefloxacin aldehyde thiosemicarbazone derivatives and its preparation method and application | |
CN109824583A (en) | A kind of phenyl Oxamides HIV-1 inhibitor and its preparation method and application | |
WO2013144532A1 (en) | 3 -cyano- 5 -arylamino-7 -cycloalkylaminopyrrolo [1, 5 -a] pyrimidine derivatives and their use as antitumor agents |